Royal Fund Management’s Moderna MRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-7,645
Closed -$815K 326
2024
Q1
$815K Sell
7,645
-1,400
-15% -$141K 0.08% 210
2023
Q4
$900K Sell
9,045
-2,700
-23% -$227K 0.1% 192
2023
Q3
$1.21M Buy
11,745
+3,900
+50% +$435K 0.16% 147
2023
Q2
$953K Buy
7,845
+3,320
+73% +$443K 0.12% 168
2023
Q1
$695K Buy
+4,525
New +$746K 0.1% 184

Other funds holding MRNA

Royal Fund Management's MRNA Position: Q2 2024 in Review

Royal Fund Management sold out of Moderna (MRNA) in Q2 2024, closing a stake of 7,645 shares — an estimated $815K sold.

Royal Fund Management first reported a position in MRNA in Q1 2023 and held it in 5 quarters. The position peaked at $1.21M in Q3 2023. 954 funds tracked by Wall St. Rank hold MRNA as of Q2 2024.

  • Royal Fund Management reported no remaining Moderna position as of Q2 2024 after selling out during the quarter.
  • Royal Fund Management sold 7,645 Moderna shares in Q2 2024, an estimated $815K.
  • Royal Fund Management first reported a position in Moderna in Q1 2023 and held it in 5 quarters.
  • Royal Fund Management's Moderna position peaked at $1.21M in Q3 2023.
  • 954 funds tracked by Wall St. Rank held Moderna as of Q2 2024.

Based on Royal Fund Management's 13F filing for Q2 2024, filed 18 Jul 2024.